Century Therapeutics Inc (NASDAQ: IPSC) kicked off on Friday, up 4.76% from the previous trading day, before settling in for the closing price of $1.05. Over the past 52 weeks, IPSC has traded in a range of $0.98-$5.51.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -14.25%. While this was happening, its average annual earnings per share was recorded 30.64%. With a float of $34.81 million, this company’s outstanding shares have now reached $84.76 million.
Let’s determine the extent of company efficiency that accounts for 165 employees. In terms of profitability, gross margin is -404.17%, operating margin of -4925.59%, and the pretax margin is -4869.53%.
Century Therapeutics Inc (IPSC) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Century Therapeutics Inc is 59.06%, while institutional ownership is 31.01%. The most recent insider transaction that took place on Nov 04 ’24, was worth 1,267. In this transaction Chief Operations Officer of this company sold 1,033 shares at a rate of $1.23, taking the stock ownership to the 135,130 shares. Before that another transaction happened on Nov 04 ’24, when Company’s SVP Finance & Operations sold 283 for $1.23, making the entire transaction worth $347. This insider now owns 317,147 shares in total.
Century Therapeutics Inc (IPSC) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.44 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 30.64% per share during the next fiscal year.
Century Therapeutics Inc (NASDAQ: IPSC) Trading Performance Indicators
Take a look at Century Therapeutics Inc’s (IPSC) current performance indicators. Last quarter, stock had a quick ratio of 10.39. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 36.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.86, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -1.76 in one year’s time.
Technical Analysis of Century Therapeutics Inc (IPSC)
Looking closely at Century Therapeutics Inc (NASDAQ: IPSC), its last 5-days average volume was 0.89 million, which is a jump from its year-to-date volume of 0.32 million. As of the previous 9 days, the stock’s Stochastic %D was 9.79%. Additionally, its Average True Range was 0.13.
During the past 100 days, Century Therapeutics Inc’s (IPSC) raw stochastic average was set at 9.30%, which indicates a significant decrease from 15.79% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 73.44% in the past 14 days, which was lower than the 83.69% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3776, while its 200-day Moving Average is $2.3758. However, in the short run, Century Therapeutics Inc’s stock first resistance to watch stands at $1.1317. Second resistance stands at $1.1633. The third major resistance level sits at $1.2067. If the price goes on to break the first support level at $1.0567, it is likely to go to the next support level at $1.0133. Now, if the price goes above the second support level, the third support stands at $0.9817.
Century Therapeutics Inc (NASDAQ: IPSC) Key Stats
The company with the Market Capitalisation of 97.98 million has total of 85,029K Shares Outstanding. Its annual sales at the moment are 2,240 K in contrast with the sum of -136,670 K annual income. Company’s last quarter sales were recorded 790 K and last quarter income was -31,230 K.
